Results 171 to 180 of about 48,467 (263)

CD20 Loss as a Mechanism of Resistance to Mosunetuzumab in Relapsed Follicular Lymphoma. [PDF]

Mediterr J Hematol Infect Dis
Canichella M, Fratoni S, Mazzone C, Di Rocco A, Abruzzese E.   +4 more
europepmc   +1 more source

Deceptive Thyroid Pathologies: Anaplastic Thyroid Carcinoma Mimics and Clinical Implications

Head &Neck, Volume 48, Issue 8, Page 2180-2189, August 2026.
ABSTRACT Background Beyond follicular‐derived thyroid carcinomas, lymphomas, and metastatic disease, there are rare pathologies of the thyroid gland that represent a challenge. We report patients with unusual malignancies that mimic similar aggressive cancers. Methods Retrospective case series.
David Z. Allen, S. Mohsen Hosseini, Mark Zafereo, Miriam Lango, Elizabeth Gardner Grubbs, Priyanka Iyer, Shreyaskumar R. Patel, Vinod Ravi, Naifa Lamki Busaidy, Rui Jennifer Wang, Michelle D. Williams, Maria E. Cabanillas, Anastasios Maniakas   +12 more
wiley   +1 more source

Chemotherapy-Sparing Strategies in Follicular Lymphoma: Emerging Targeted and Immune-Based Approaches. [PDF]

Eur J Haematol
Martino EA, Caserta S, Skafi M, Alvaro ME, Bruzzese A, Amodio N, Lucia E, Olivito V, Labanca C, Mendicino F, Vigna E, Morabito F, Gentile M.   +12 more
europepmc   +1 more source

First‐line treatment with epcoritamab in combination with bendamustine plus rituximab induces sustained remissions beyond 3 years in patients with follicular lymphoma

HemaSphere, Volume 10, Issue 8, August 2026.
Abstract First‐line (1L) bendamustine plus rituximab (BR) leads to high response rates in follicular lymphoma (FL), but maintaining durable remissions remains challenging. We report the 3‐year follow‐up from arm 3 of the phase 1b/2 EPCORE NHL‐2 trial (NCT04663347) of epcoritamab, a subcutaneously administered CD3×CD20 bispecific antibody, combined with
Umberto Vitolo, Lorenzo Falchi, Per‐Ola Andersson, Marcel Nijland, Fritz Offner, Sylvia Snauwaert, Jacob H. Christensen, Michael R. Clausen, Alexander Fosså, Pilar G. Prieto, Eliza A. Hawkes, Judit M. Jørgensen, Yasmin H. Karimi, Catharina Lewerin, Joost S. P. Vermaat, Björn E. Wahlin, Poliana Patah, Christopher Morehouse, Malene Risum, Zhu Li, Jennifer Marek, Joshua D. Brody   +21 more
wiley   +1 more source

Obinutuzumab, lenalidomide, and venetoclax for the initial treatment of patients with advanced-stage follicular lymphoma: Results of the Phase Ib/II LEVERAGE study. [PDF]

Hemasphere
Cheah CY, Blombery P, Johnston A, Wight J, Lewis KL, Bennett R, Xie J, Vlachos S, Hunter SM, Gonzales J, Binks S, Seymour JF.   +11 more
europepmc   +1 more source

Clinicopathological Features of Lupus Erythematosus Panniculitis (LEP): A Retrospective Analysis of 54 Cases

Health Science Reports, Volume 9, Issue 8, August 2026.
ABSTRACT Background Lupus Erythematosus Panniculitis (LEP) is a rare subtype of Cutaneous Lupus Erythematosus. It is a challenging disease to diagnose and treat due to limited understanding of its clinical and histopathological characteristics. Methods We conducted a retrospective review of 54 biopsy‐proven LEP cases evaluated at a dermatology referral
Maryam Nasimi, Narjes Ramezani, Kambiz Kamyab, Alireza Abdshah, Maryam Ghiasi, Sahar Montazeri, Hanie Babaie, Fatemeh Saberi   +7 more
wiley   +1 more source

Real-world outcomes of bispecific antibody therapy after chimeric antigen receptor T-cell therapy in follicular lymphoma. [PDF]

Blood Cancer J
Sharp J, Bhatta S, Huang JJ, Thomas CJ, Elghawy O, Fitzgerald L, Reef D, Teferra A, Voorhees TJ, Gupta S, Grover NS, Barta SK, Shadman M, Epperla N.   +13 more
europepmc   +1 more source

The Therapeutic Potential of Stem Cell Therapy for Doxorubicin‐Induced Cardiotoxicity: A Narrative Review

Health Science Reports, Volume 9, Issue 8, August 2026.
ABSTRACT Background and Aims Doxorubicin (DOX) is a potent anthracycline chemotherapeutic agent whose clinical utility is significantly constrained by severe side effects, most notably DOX‐induced cardiotoxicity (DIC). Pathophysiological mechanisms of DIC include oxidative stress, mitochondrial dysfunction, programmed cell death, and inflammation ...
Ali Mirzaei, Pouria Rezaei, Reza Golchin Vafa, Saleheh Jahani, Reza Arefnezhad, Hossein Fatemian, Mohammad Hossein Nikoo, Amirhossein Sahebkar, Fatemeh Rezaei‐Tazangi   +8 more
wiley   +1 more source